prospective study for the assessment of gene dysregulation in B-cell oncogenesis using complementary DNA microarray

B-cell lymphoma displays striking heterogeneity at the clinical, genetic arid molecular levels. Clinical prognostic models can define a population at high risk for relapse following empiric chemotherapy, although such models do not account for underlying biologic differences among tumors. Despite recent advances in empiric chemotherapy, including interval reduction of CHOP [cyclophosphamide, doxorubicin, vincristine, prednisone] and the incorporation of anti-CD2O monoclonal antibodies, a significant proportion of patients still die of their disease. Gene expression profiling has shed light on the molecular heterogeneity within B cell lymphoma by highlighting similarities between subsets of tumors and normal B cells, identifying features associated with unfavorable responses to empiric combination chemotherapy and defining robust subtypes with comprehensive transcriptional signatures. Commonly observed genetic abnormalities that likely contribute to pathogenesis include translocations of BCL6, BCL2 and MHC class II mutations. Our study showed over expression of some genes e.g. BCL2, interleukin I, interferon receptor and low expression of MHC class H, p53, Fas and casp8-FADD. Our increasing molecular understanding of the heterogeneous subsets within B cell lymphoma will likely improve the current empiric therapy by identifying rational therapeutic targets in specific disease subtypes

Treatment results of male breast carcinoma: the National Cancer Institute and Kasr El-Aini Center of Radiation Oncology and Nuclear Medicine; Cairo University [Egypt]

The present study includes total 286 male patients suffering from breast carcinoma and the analysis includes 92 cases of which the pathology was available. Patients presented to NCI and NEMROCK between January 1975 and December 1985. Clinicopathological study and analysis of treatment results were done of 92 patients who were followed-up for at least 6 months after the end of treatment. The mean age was 53.5 +/- 5 years. The most common pathological type was infiltrative duct carcinoma [73.3%]

Malignant salivary gland tumours: experience of Cairo University Center of Radiation Oncology and Nuclear Medicine [Nemrock]

A retrospective clinicoepidemiological study and treatment results of assessment of patients suffering from malignant salivary gland tumors was carried out at Kasr El-Aini Center of Radiation Oncology and Nuclear Medicine [NEMROCK] during the period1980-1984inclusive. Forty-five primary malignant salivary gland tumors were reviewed having a relative frequency incidence of 0.7% of all malignant cases [6457 cases] reported in NEMROCK during the studied period. A mean age of 47.6 +/- 18 years and a male to female ratio of 1: 1.25were obtained.Adenoidcysticcarcinomawasthemostfrequent histopathological type [46.7%], followed by mucoepidermoid carcinoma [15.6%]. Major salivary glands were affected in 53.3% of cases. The parotid gland was the most frequent major gland to be affected [79.2%],while nasal and paranasal sinuses malignant salivary gland tumors represented nearly 50% of minor gland malignancy.In24 evaluable patients,the median survival period was 33.4 +/- 24 months. Better prognosis was seen in females especially in the younger ages [below 40 years] in the whole group of malignant salivary gland tumors, while early clinical T-stage was of better prognosis in the malignant major salivary gland tumors